• NICE decision on enzalutamide for non-metastatic prostate cancer

    The decision is based on preliminary data from the PROSPER trial

  • Bladder cancer: ipilimumab-heavy immunotherapy combo offers best response

    Updated results from CheckMate 032.

  • AKI impairs long-term functional recovery after partial nephrectomy

    A study from Memorial Sloan Kettering Cancer Center.

  • FDA approves avelumab-axitinib for frontline RCC

    Approval is based on phase 3 JAVELIN Renal 101 study.

  • NICE approves nivolumab with ipilimumab for renal cancer

    Nivolumab with ipilimumab approved for use within the Cancer Drugs Fund for untreated advanced renal cell carcinoma

  • Metastatic kidney cancer: frontline atezolizumab-bevacizumab tops sunitinib in phase 3

    Data from IMmotion151.

  • Localised prostate cancer: biomarkers of outcome with radiotherapy

    Research led by the Institute of Cancer Research Clinical Trials and Statistics Unit in London

  • Human papillomavirus and the risk of urothelial carcinoma of the bladder

    Results from a case-control study.

  • Prostate cancer: NICE issues an updated quality standard
    Prostate cancer: NICE issues an updated quality standard

    Quality statements for prostate cancer are expected to improve outcomes.

  • BPH medications tied to delayed prostate cancer diagnosis

    5-ARIs reduce serum PSA concentrations by 50%.

  • NICE issues updated guidance on prostate cancer

    The guideline covers the diagnosis and management of prostate cancer in secondary care, and follow-up in primary care

  • Urothelial cancer: 2-year data support pembrolizumab over chemotherapy

    Long-term KEYNOTE-045 data maintain consistency.

  • Prostate cancer: variations in QoL across UK

    Prostate cancer survivors in Scotland, Wales, and Northern Ireland had poor quality of life than men in England

  • Small renal masses: long-term data support percutaneous ablation

    Retrospective review of survival endpoints with ablation vs partial nephrectomy.

  • Meta-analysis: safety of immune checkpoint inhibitors in cancer

    Large meta-analysis of 125 studies, 20k patients.

  • Prostate cancer: AR burden predicts poor response to antiandrogen therapy

    AR perturbations were associated with worse PFS.

  • Multiparametric MRI improves prostate cancer detection

    Imaging-based diagnostic approach reduces unnecessary biopsies, overtreatment.

  • Load more